Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market by GBIResearch

VIEWS: 966 PAGES: 103

More Info
									             Antihypertensives Market to 2016 - Generic Erosion
             Following Patent Expiry of Major ARBs to Impact the
                                   Market
 Reference Code: GBIHC053MR                                                                             Publication Date: December 2010


                                     Global Anti-Hypertensives Market: Executive Summary
The global anti-                     GBI Research has found that the global anti-hypertensive market will grow in the near future, owing
hypertensive market is               to increased acceptability of combination therapies. In 2016, the market is expected to rise slightly
expected to witness a                due to increased use of fixed dose combinations and the probable launch of novel therapeutics for
series of patent expiries            the treatment of PAH (Pulmonary Arterial Hypertension). Anti-hypertensive drugs have been
between 2007 and 2015                recorded to be the highest selling drugs. Market growth is expected to slow down between 2007-
                                     2015 due to various factors, such as the patent expiries of key drugs across all disease segments,
                                     the entry of generics, and the decreased annual cost of therapy in major markets such as the US,
                                     Japan and the top five countries in Europe (the UK, Spain, Italy Germany and France). Novartis’s
                                     blockbuster drug Diovan ($6 billion in 2009) is expected to show a steep decline in the near future
                                     due to the end of market exclusivity following patent protection expiry. The patent on Diovan’s
                                     active ingredient valsartan is expected to expire in 2011 (EU), 2012 (US) and late 2013 (Japan).
                                     Global sales of Cozaar and Hyzaar of Merck showed a slight decline in the first quarter of 2010.
                                     This is primarily because of patent expiry of Cozaar (ARB-Angiotensin Receptor Blockers) in the
                                     US. ARB’s (Angiotensin receptor blockers) are the most popular therapies for hypertension and are
                                     the last class of anti-hypertensives to lose patent protection. Thus, the effect on the anti-
                                     hypertensive market may be huge due to the upcoming patent expiries of blockbusters belonging to
                                     these classes.
                                     The PAH market is set to grow until 2015. There will be a decline in the market in 2016 due to the
                                     patent expiry of Tracleer, which is the most prescribed drug in the PAH population.
                                     The Global Anti-Hypertensive Market is Set to Show Flat Growth in the near Future
                                     In 2009, the global anti-hypertensive market was estimated to be worth $27.2 billion, representing a
                                     Compound Annual Growth Rate (CAGR) of 5.0% between 2002 and 2009. The market is forecast
                                     to reach $30 billion by 2016, indicating a CAGR of 1.5% between 2009 and 2016. The primary
                                     reason for slight and gradual growth in the market is the patent expiries of major blockbusters,
                                     which are expected to decrease the annual cost of therapy after 2007.
                                     The global anti-hypertensive market is expected to witness a series of patent expiries between
                                     2007 and 2015, which includes most of the top selling blockbuster drugs in the anti-hypertensive
                                     market. The major drugs that are set to lose patent protection include Novartis’s Diovan (2012),
                                     Sanofi Aventis’s Avapro (2012), Novartis’s Exforge (2012), Takeda/AstraZeneca’s
                                     Blopress/Atacand (2012), Pfizer’s Revatio (2012), Actelion’s Tracleer (2015), and United
                                     Therapeutics Remodulin (2014). All these drugs together accounted for more than $19.4 billion in
                                     revenues in 2009. Merck’s Cozaar patent expired in April 2010. The sales of Cozaar for the year
                                     2009 were $3.6 billion. Pfizer’s Norvasc, which was once the world’s most prescribed drug for
                                     hypertension and angina, saw a sales decline of 12% in 2009 due to genericization in 2007. Thus,
                                     the series of upcoming patent expiries in the hypertension as well as PAH markets are set to lead
                                     to a decline in the market in the near future. However, due to increased usage of fixed dose-
                                     combinations and the entry of generics, the market is expected to rise slightly after 2015.
                                     The current anti-hypertensive pipeline does offer some promising novel products, such as SPP635,
                                     Actos, LCZ696, QT1571, ACT-293987, PS-433540, Macitentan and Riociguat, indicated for the
                                     treatment of hypertension and PAH. However, the revenues generated from these products are not
                                     expected to completely make up for the revenue losses due to patent expiries. Thus, the overall
                                     global anti-hypertensive market is expected to show flat growth during the forecast period.
                                     Top Six Companies Control Approximately 74% of the Market
                                     The current global anti-hypertensive market is significantly consolidated as the top six players
                                     control approximately 74% of the market. Novartis is the current market leader with its blockbuster
                                     product, Diovan. It is available in more than 100 countries. It has recorded sales of six billion in
                                     2009. Other major products in the anti-hypertensive market of Novartis are Exforge,


Antihypertensives Market to 2016 - Generic Erosion                                                        GBIHC053MR /Published DEC 2010
Following Patent Expiry of Major ARBs to Impact the
Market                                                                                                                                 Page 1
                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                     Tekturna/Rasilez, Lotrel and Lescol, controlling 43% of the total anti-hypertensive market. Merck
                                     follows Novartis with a 19% market share, primarily due to its top selling ARB, Cozaar. The sales of
                                     Cozaar are set to decline in the future as the patent on Cozaar expired in April 2010. Pfizer
                                     occupies the third position with its blockbuster drug Norvasc. Pfizer also marks its presence in the
                                     PAH market with its Revatio. Norvasc went off-patent in the year 2007. It was one of the
                                     blockbuster drugs in the anti-hypertensive market until this date. Takeda is the fourth player in the
                                     anti-hypertensive market, with its blockbuster drug Blopress. The sales of Blopress are set to
                                     increase in the coming years. Takeda is followed by Actelion and Sanofi Aventis. Actelion is the
                                     market leader in PAH with its blockbuster drugs, Tracleer and Ventavis. Actelion and Sanofi
                                     Aventis control 8% and 7% of the total market.
                                     However, the market shares of the total players are expected to witness changes in the near future
                                     due to upcoming patent expiries. Novartis’s Diovan and Tekturna/Rasilez are set to expire in 2012.
                                     Exforge is set to expire in 2010. Merck’s Cozaar went off-patent in the year 2010. Merck and Pfizer
                                     have been registering negative growth in recent years due to patent expiries. Novartis, Takeda and
                                     Actelion have shown positive growth.

                                       Anti-Hypertensive Market, Global, Market Share of Top Manufacturers (%), 2010


                                                                                                           Novartis
                                                                                                            31%


                                                              OTHERS
                                                               46%




                                                                                                        Pfizer
                                                                                                        13%
                                                                                         Merck
                                                                                         10%

                                       Source: GBI Research

                                     Novartis to Lead the Anti-Hypertensive Market
                                     The anti-hypertensive drug category was the largest selling subcategory of the cardiovascular
                                     market in 2009. Novartis is the market leader in the anti-hypertensive market, with a large number
                                     of marketed products. Key products of Novartis include Diovan, Exforge, Tekturna/Rasilez, Lotrel
                                     and Lescol. Takeda’s Blopress is also a key product in the anti-hypertensive market, registering
                                     increased sales. Pfizer’s Norvasc was the market leader until 2007. Norvasc went off-patent in
                                     2007, giving a major share of the market to Novartis’s Diovan and Merck’s Cozaar. With Cozaar,
                                     the first ARB to lose patent in April 2010, Novartis will be the market leader in the anti-hypertensive
                                     market. Novartis’s Diovan is set to lose patent in 2012. Novartis is trying to position Tekturna to be
                                     the lead drug for hypertension as Diovan is set to lose patent protection in 2012. Sanofi Aventis’s
                                     Avapro is also one of the leading drugs in the anti-hypertensive market, registering high sales over
                                     the years. It is also expected to go off-patent in the year 2012. Actelion’s Tracleer, the most
                                     prescribed PAH therapy in the world, is also set to expire in the year 2015. Thus Novartis, with a
                                     large number of blockbuster products, will lead the anti-hypertensive market.




Antihypertensives Market to 2016 - Generic Erosion                                                         GBIHC053MR /Published DEC 2010
Following Patent Expiry of Major ARBs to Impact the
Market                                                                                                                                  Page 2
                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                     1 Table of Contents
                                     1   Table of Contents ........................................................................................................................ 3
                                         1.1    List of Tables..................................................................................................................... 5
                                         1.2    List of Figures ................................................................................................................... 7
                                     2   Global Anti-Hypertensives Market: Introduction........................................................................... 9
                                         2.1    GBI Research Report Guidance ..................................................................................... 10
                                     3   Global Anti-Hypertensives Market: Market Overview ................................................................ 11
                                         3.1    Introduction ..................................................................................................................... 11
                                         3.2    Revenue Forecasts for the Global Anti-Hypertensive Market ......................................... 12
                                            3.2.1    Sales Value ............................................................................................................. 12
                                            3.2.2    Annual Cost of Therapy........................................................................................... 13
                                            3.2.3    Treatment Usage Patterns ...................................................................................... 14
                                            3.2.4    Treatment-Seeking Population ................................................................................ 16
                                            3.2.5    Diagnosed Population ............................................................................................. 17
                                            3.2.6    Prescription Population............................................................................................ 18
                                         3.3    Anti-Hypertension Disorders Market Drivers ................................................................... 19
                                            3.3.1    Steady Increase in the Hypertension and Pulmonary Arterial Hypertension
                                                     Prevalence Population............................................................................................. 19
                                            3.3.2    Uptake of Fixed Dose Combination Therapies due to Better Efficacy in Hypertension
                                                     and PAH .................................................................................................................. 19
                                            3.3.3    Patent Expiries of Branded Drugs and Entry of Generics will Reduce the Annual
                                                     Cost of Therapy with Anti-Hypertensives................................................................. 19
                                         3.4    Anti-Hypertension Disorders Market Restraints .............................................................. 20
                                            3.4.1    Low Compliance in Hypertensive Patients .............................................................. 20
                                            3.4.2    Patent Expiries of Major Blockbusters Including Diovan, Avapro, Blopress/Atacand,
                                                     Cozaar/Hyzaar and Tracleer, Pose a Threat to Market Revenues .......................... 20
                                            3.4.3    Low Treatment Seeking Behavior and Diagnosis in PAH........................................ 20
                                         3.5    Generics Share in the Global Anti-Hypertension Market................................................. 21
                                     4   Global Anti-Hypertensives Market: Therapeutic Landscape ...................................................... 22
                                         4.1    Hypertension................................................................................................................... 22
                                            4.1.1    Introduction.............................................................................................................. 22
                                            4.1.2    Sales Value ............................................................................................................. 22
                                            4.1.3    Annual Cost of Therapy........................................................................................... 25
                                            4.1.4    Treatment Usage Patterns ...................................................................................... 26
                                            4.1.5    Market Share by Geography.................................................................................... 30
                                         4.2    Pulmonary Arterial Hypertension (PAH) Market.............................................................. 33
                                            4.2.1    Introduction.............................................................................................................. 33
                                            4.2.2    Sales Value ............................................................................................................. 35
                                            4.2.3    Annual Cost of Therapy........................................................................................... 36
                                            4.2.4    Treatment Usage Patterns ...................................................................................... 37
                                            4.2.5    Market Share by Geography.................................................................................... 41
                                     5   Global Anti-Hypertensives Market: Geographical Landscape ................................................... 44
                                         5.1    Geographical Break-up ................................................................................................... 44
                                         5.2    The US............................................................................................................................ 47
                                            5.2.1    Sales Value ............................................................................................................. 47
                                            5.2.2    Annual Cost of Therapy........................................................................................... 48
                                            5.2.3    Treatment Usage Patterns ...................................................................................... 49
                                            5.2.4    Treatment-Seeking Population ................................................................................ 50
                                         5.3    Top Five Countries in Europe ......................................................................................... 53
                                            5.3.1    Sales Value ............................................................................................................. 53
                                            5.3.2    Annual Cost of Therapy........................................................................................... 54
                                            5.3.3    Treatment Usage Patterns ...................................................................................... 55
                                         5.4    Japan .............................................................................................................................. 59
                                            5.4.1    Sales Value ............................................................................................................. 59
                                            5.4.2    Annual Cost of Therapy........................................................................................... 60

Antihypertensives Market to 2016 - Generic Erosion                                                                                    GBIHC053MR /Published DEC 2010
Following Patent Expiry of Major ARBs to Impact the
Market                                                                                                                                                                       Page 3
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                          5.4.3    Treatment Usage Patterns ...................................................................................... 61
                                     6 Global Anti-Hypertensives Market: Pipeline Analysis ................................................................ 65
                                       6.1    Introduction ..................................................................................................................... 65
                                          6.1.1    Research and Development Pipeline – Hypertension ............................................. 66
                                          6.1.2    Research and Development Pipeline – Pulmonary Arterial Hypertension ............... 72
                                       6.2    Profiles of Key Late-Stage Drugs in the Anti-Hypertension Market................................. 76
                                          6.2.1    SPP635 ................................................................................................................... 76
                                          6.2.2    Pioglitazone ............................................................................................................. 77
                                          6.2.3    LCZ696.................................................................................................................... 78
                                          6.2.4    QT1571 (imatinib).................................................................................................... 78
                                          6.2.5    Selexipag (NS-304, ACT-293987) ........................................................................... 79
                                          6.2.6    PS-433540 (DARA) ................................................................................................. 80
                                          6.2.7    Macitentan (ACT-064992, Actelion 1)...................................................................... 80
                                          6.2.8    Riociguat (BAY63-2521) .......................................................................................... 81
                                     7 Global Anti-Hypertensives Market: Competitive Landscape ...................................................... 83
                                       7.1    Market Share Analysis: Hypertension Disorders............................................................. 83
                                       7.2    Competitive Profiling ....................................................................................................... 84
                                          7.2.1    Novartis ................................................................................................................... 84
                                          7.2.2    Merck....................................................................................................................... 85
                                          7.2.3    AstraZeneca ............................................................................................................ 86
                                          7.2.4    United Therapeutics ................................................................................................ 87
                                          7.2.5    Actelion.................................................................................................................... 89
                                          7.2.6    Pfizer ....................................................................................................................... 90
                                     8 Global Anti-Hypertensives Market: Strategic Consolidations..................................................... 92
                                       8.1    Overview ......................................................................................................................... 92
                                       8.2    Deals by Type ................................................................................................................. 93
                                          8.2.1    Eli Lilly Acquires ICOS in January 2007 .................................................................. 93
                                          8.2.2    Abbott Laboratories Acquires Solvay Pharmaceuticals in February 2010 ............... 93
                                          8.2.3    Endo Pharmaceuticals to Acquire Qualitest Pharmaceuticals in 2010 .................... 94
                                          8.2.4    Jubilant Organosys Acquires Trinity Laboratories and Trigen Laboratories in March
                                                   2007 ........................................................................................................................ 94
                                       8.3    R&D Licensing Agreements ............................................................................................ 94
                                          8.3.1    Deals by Indication .................................................................................................. 94
                                          8.3.2    Deals by Phase ....................................................................................................... 95
                                          8.3.3    Deals by Geography................................................................................................ 95
                                          8.3.4    Phase II ................................................................................................................... 96
                                          8.3.5    Approved ................................................................................................................. 97
                                     9 Global Anti-Hypertensives Market: Appendix ............................................................................ 99
                                       9.1    Market Definitions ........................................................................................................... 99
                                       9.2    Abbreviations .................................................................................................................. 99
                                       9.3    Research Methodology ................................................................................................. 101
                                          9.3.1    Coverage ............................................................................................................... 101
                                          9.3.2    Secondary Research ............................................................................................. 101
                                          9.3.3    Primary Research.................................................................................................. 101
                                          9.3.4    Expert Panel Validation ......................................................................................... 102
                                       9.4    Contact Us .................................................................................................................... 102
                                       9.5    Disclaimer ..................................................................................................................... 102
                                       9.6    Sources......................................................................................................................... 103




Antihypertensives Market to 2016 - Generic Erosion                                                                                  GBIHC053MR /Published DEC 2010
Following Patent Expiry of Major ARBs to Impact the
Market                                                                                                                                                                    Page 4
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                     1.1     List of Tables
                                     Table 1:    Anti-Hypertensive Market, Global, Sales Value ($bn), 2002–2009 ................................ 12
                                     Table 2:    Anti-Hypertensive Market, Global, Sales Value ($bn), 2009–2016 ................................ 12
                                     Table 3:    Anti-Hypertensive Market, Global, Annual Cost of Therapy ($), 2002–2009.................. 13
                                     Table 4:    Anti-Hypertensive Market, Global, Annual Cost of Therapy ($), 2009–2016.................. 13
                                     Table 5:    Anti-Hypertensive Market, Global, Treatment Usage Patterns (millions), 2002–2009.... 15
                                     Table 6:    Anti-Hypertensive Market, Global, Treatment Usage Patterns (millions), 2009–2016.... 15
                                     Table 7:    Anti-Hypertensive Market, Global, Hypertension Sales Value ($bn), 2002–2009 .......... 23
                                     Table 8:    Anti-Hypertensive Market, Global, Hypertension Sales Value ($bn), 2009–2016 .......... 24
                                     Table 9:    Anti-Hypertensive Market, Global, Hypertension Annual Cost of Therapy ($), 2002–2009
                                                 ....................................................................................................................................... 25
                                     Table 10:   Anti-Hypertensive Market, Global, Hypertension Annual Cost of Therapy ($), 2009–2016
                                                 ....................................................................................................................................... 26
                                     Table 11:   Anti-Hypertensive Market, Global, Hypertension Treatment Usage Patterns (millions),
                                                 2002–2009 ..................................................................................................................... 26
                                     Table 12:   Anti-Hypertensive Market, Global, Hypertension Treatment Usage Patterns (millions),
                                                 2009–2016 ..................................................................................................................... 27
                                     Table 13:   Anti-Hypertensive Market, Global, Hypertension Market Geographical Segmentation
                                                 ($bn), 2002–2009........................................................................................................... 31
                                     Table 14:   Anti-Hypertensive Market, Global, Hypertension Market Geographical Segmentation
                                                 ($bn), 2009–2016........................................................................................................... 32
                                     Table 15:   Anti-Hypertensive Market, Global, PAH Sales Value ($bn), 2002–2009 ........................ 35
                                     Table 16:   Anti-Hypertensive Market, Global, PAH Sales Value ($bn), 2009–2016 ........................ 35
                                     Table 17:   Anti-Hypertensive Market, Global, PAH Annual Cost of Therapy ($), 2002–2009 ......... 36
                                     Table 18:   Anti-Hypertensive Market, Global, PAH Annual Cost of Therapy ($), 2009–2016 ......... 36
                                     Table 19:   Anti-Hypertensive Market, Global, PAH Treatment Usage Patterns (thousands), 2002–
                                                 2009 ...............................................................................................................................37
                                     Table 20:   Anti-Hypertensive Market, Global, PAH Treatment Usage Patterns (thousands), 2009–
                                                 2016 ...............................................................................................................................37
                                     Table 21:   Anti-Hypertensive Market, Global, PAH Market Geographical Segmentation ($m), 2002–
                                                 2009 ...............................................................................................................................42
                                     Table 22:   Anti-Hypertensive Market, Global, PAH Market Geographical Segmentation ($m), 2009–
                                                 2016 ...............................................................................................................................42
                                     Table 23:   Anti-Hypertensive Market, Global, Sales Value by Geography ($bn), 2002–2009 ......... 45
                                     Table 24:   Anti-Hypertensive Market, Global, Sales Value by Geography ($bn), 2009–2016 ......... 45
                                     Table 25:   Anti-Hypertensive Market, the US, Sales Value ($bn), 2002–2009................................ 47
                                     Table 26:   Anti-Hypertensive Market, the US, Sales Value ($bn), 2009–2016................................ 47
                                     Table 27:   Anti-Hypertensive Market, the US, Annual Cost of Therapy ($), 2002–2009 ................. 48
                                     Table 28:   Anti-Hypertensive Market, the US, Annual Cost of Therapy ($), 2009–2016 ................. 48
                                     Table 29:   Anti-Hypertensive Market, the US, Treatment Usage Patterns (millions), 2002–2009 ... 49
                                     Table 30:   Anti-Hypertensive Market, the US, Treatment Usage Patterns (millions), 2009–2016 ... 50
                                     Table 31:   Anti-Hypertensive Market, Top Five Countries in Europe, Sales Value ($bn), 2002–2009
                                                 ....................................................................................................................................... 53
                                     Table 32:   Anti-Hypertensive Market, Top Five Countries in Europe, Sales Value ($bn), 2009–2016
                                                 ....................................................................................................................................... 53
                                     Table 33:   Anti-Hypertensive Market, Top Five Countries in Europe, Annual Cost of Therapy ($),
                                                 2002–2009 ..................................................................................................................... 54
                                     Table 34:   Anti-Hypertensive Market, Top Five Countries in Europe, Annual Cost of Therapy ($),
                                                 2009–2016 ..................................................................................................................... 55
                                     Table 35:   Anti-Hypertensive Market, Top Five Countries in Europe, Treatment Usage Pattern
                                                 (millions), 2002–2009..................................................................................................... 55
                                     Table 36:   Anti-Hypertensive Market, Top Five Countries in Europe, Treatment Usage Pattern
                                                 (millions), 2009–2016..................................................................................................... 55
                                     Table 37:   Anti-Hypertensive Market, Japan, Sales Value ($bn), 2002–2016 ................................. 59
                                     Table 38:   Anti-Hypertensive Market, Japan, Sales Value ($bn), 2009–2016 ................................. 59
                                     Table 39:   Anti-Hypertensive Market, Japan, Annual Cost of Therapy ($), 2002–2009 .................. 60
                                     Table 40:   Anti-Hypertensive Market, Japan, Annual Cost of Therapy ($), 2009–2016 .................. 60
                                     Table 41:   Anti-Hypertensive Market, Japan, Treatment Usage Pattern (millions), 2002–2009 ...... 61
                                     Table 42:   Anti-Hypertensive Market, Japan, Treatment Usage Pattern (millions), 2009–2016 ...... 61
                                     Table 43:   Anti-Hypertensive Market, Global, R&D Pipeline by Phase in Hypertension Market,
                                                 October 2010 ................................................................................................................. 67


Antihypertensives Market to 2016 - Generic Erosion                                                                                     GBIHC053MR /Published DEC 2010
Following Patent Expiry of Major ARBs to Impact the
Market                                                                                                                                                                          Page 5
                                                                                      © GBI Research. This is a licensed product and is not to be photocopied
                                     Table 44: Anti-Hypertensive Market, Global, R&D Pipeline by Phase in Pulmonary Arterial
                                               Hypertension Market, 2010 ............................................................................................ 72
                                     Table 45: Anti-Hypertensive Market, Global, Major M&A Deals, 2005-2010.................................. 93
                                     Table 46: Anti-Hypertensive Market, Global, Licensing Agreements for Drugs in Phase II Stage,
                                               2005–2010 ..................................................................................................................... 96
                                     Table 47: Anti-Hypertensive Market, Global, Licensing Agreements for Approved Drugs, 2005–
                                               2009 ...............................................................................................................................97




Antihypertensives Market to 2016 - Generic Erosion                                                                                   GBIHC053MR /Published DEC 2010
Following Patent Expiry of Major ARBs to Impact the
Market                                                                                                                                                                     Page 6
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                     1.2       List of Figures
                                     Figure 1: Anti-Hypertensive Market, Global, Drivers and Restraints, 2010 ................................... 11
                                     Figure 2: Anti-Hypertensive Market, Global, Sales Value ($bn), 2002–2016 ................................ 12
                                     Figure 3: Anti-Hypertensive Market, Global, Annual Cost of Therapy ($), 2002–2016.................. 13
                                     Figure 4: Anti-Hypertensive Market, Global, Therapeutic Usage Patterns (millions), 2002– 2016
                                                ....................................................................................................................................... 14
                                     Figure 5: Anti-Hypertensive Market, Global, Therapeutic Usage Patterns (millions), 2002–2016
                                                ....................................................................................................................................... 15
                                     Figure 6: Anti-Hypertensive Market, Global, Treatment-Seeking Population (millions), 2002–
                                                2016 ...............................................................................................................................16
                                     Figure 7: Anti-Hypertensive Market, Global, Diagnosis Population (millions), 2002–2016 ............ 17
                                     Figure 8: Anti-Hypertensive Market, Global, Prescription Population (millions), 2002–2016...... 18
                                     Figure 9: Anti-Hypertensive Market, Global, Branded v/s Generic Drugs, 2010............................ 21
                                     Figure 10: Anti-Hypertensive Market, Global, Hypertension Sales Value ($bn),                                               2002–2016 .... 23
                                     Figure 11: Anti-Hypertensive Market, Global, Hypertension Annual Cost of Therapy ($),                                                    2002–
                                                2016 ...............................................................................................................................25
                   
								
To top